About Astex Pharmaceuticals
Astex Pharmaceuticals is a Healthcare company based in Pleasanton (United States) founded in 1991, and was acquired by Otsuka in September 2013. Speciality pharma comany focused on drug discovery and development with focus on cancer and CNS disorders. Astex Pharmaceuticals has raised $3 million across 2 funding rounds from investors including Otsuka, SuperGen and NEA. The company has 115 employees. Its chief executive, as recorded, is Harren Jhoti. Astex Pharmaceuticals offers products and services including Kisqali, Balversa, Truqap, and Tolinapant. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
Astex Pharmaceuticals is focused on drug discovery and development with focus on cancer and CNS disorders. Pipeline products at various stages of clinical trials include Guadecitabine (a DNA methyltransferase inhibitor) for naive and refractory AML, solid tumors and hematologic malignancies, (Phase 3 trials), onalespib for lung and melanoma, AT7519 for solid tumors, AT13148 for solid tumors, ASTX727 for myelodysplastic syndrome (MDS) and ASTX660 for solid tumors etc among other partner products. Company got acquired by Otsuka pharmaceuticals in 2013 and now operates as a wholly owned subsidiary.
Products & Services of Astex Pharmaceuticals
Astex Pharmaceuticals offers a comprehensive portfolio of products and services, including Kisqali, Balversa, Truqap, and Tolinapant.
CDK4/6 inhibitor for oncology treatment in solid tumors.
FGFr inhibitor targeting oncology in solid tumors.
PKB/Akt inhibitor for oncology applications.
Dual IAP antagonist for T-cell lymphomas treatment.
Funding Insights of Astex Pharmaceuticals
Astex Pharmaceuticals has successfully raised a total of $3M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in November 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 2
- Last Round Series A — $3M
- Investors Count 1
All 2 funding rounds of Astex Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2009 | $3M | Series A | – | – | – |
| Jun 2008 | Unspecified | – | New Enterprise Associates | – |
3 investors in total: 3 institutional.
Investors in Astex Pharmaceuticals
Astex Pharmaceuticals has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Otsuka, SuperGen and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Generic pharmaceuticals and nutraceuticals are manufactured and marketed by Otsuka. | 1921 | otsuka.com | Chiyoda City, Japan | |
Cancer therapeutics targeting epigenetic mechanisms are developed for oncology applications. | 1991 | supergen.com | Dublin, United States |
Investor details for Astex Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Astex Pharmaceuticals
19 people are tracked at Astex Pharmaceuticals (15 in leadership, 4 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Harren Jhoti | CEO & President | Leadership |
Aram Oganesian | Vice President, Clinical Pharmacology & Nonclinical Development | Leadership |
Marc O’reilly | Senior Vice President, Discovery Technologies | Leadership |
Michelle Jones | Chief Operating Officer | Leadership |
Neil Jones | Senior Vice President, Finance & Operations | Leadership |
Amardeep Neburi | Senior Director, Clinical Data Management | Leadership |
Tom Davies | Director (molecular Sciences) | Leadership |
Jeremy Carmichael | Senior Vice President, Corporate Development; Head Of Business Development | Leadership |
John Lyons | Senior Vice President | Leadership |
Gianni Chessari | Senior Vice President, Drug Discovery | Leadership |
Harold Keer | Senior Vice President, Clinical Development | Leadership |
Jason Taylor | Senior Medical Director | Leadership |
Martin Sims | Senior Director, Translational Research | Leadership |
Chris Murray | Senior Vice President, Computational Chemistry & Informatics | Leadership |
Daisy Leung | Vice President, Portfolio And Program Management | Leadership |
Jennifer Deguzman | Clinical Data Associate III | Team |
George Ward | Research | Team |
Vincent Ramirez Ph.d. | Principal Scientist, Toxicology | Team |
Iran Reyes | Lab Operations Manager | Team |
Complete people profiles for Astex Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Astex Pharmaceuticals
Competitors of Astex Pharmaceuticals
Astex Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Astex Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Astex Pharmaceuticals
The website of Astex Pharmaceuticals (astx.com) receives about 8.9K visits a month and ranks #2,592,392 among all websites worldwide, #3,554 in Biotechnology and Pharmaceuticals.
- Monthly visits8.9K
▲ 19.5% vs previous month
- Unique visitors3.3K
per month
- Global rank#2,592,392
among all websites
- Category rank#3,554
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.1
- Average visit2 min 07 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Astex Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
kinexpharma.com | kinexpharma.com | 100% | – | ||
| afnm.com | 99% | View details | |||
| alexza.com | 98% | View details | |||
diffusionpharma.com | diffusionpharma.com | 98% | – | ||
| altheadx.com | 98% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for Astex Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Astex Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Astex Pharmaceuticals
Complete news archive for Astex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Astex Pharmaceuticals
Astex Pharmaceuticals was founded in 1991 and raised its 1st funding round 17 years after it was founded.
Astex Pharmaceuticals is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.
Harren Jhoti is the CEO of Astex Pharmaceuticals, as recorded in our data.
Astex Pharmaceuticals is a funded company, having raised a total of $3M across 2 funding rounds to date.
Astex Pharmaceuticals has 115 employees.
Astex Pharmaceuticals is focused on drug discovery and development with focus on cancer and CNS disorders. Pipeline products at various stages of clinical trials include Guadecitabine (a DNA methyltransferase inhibitor) for naive and refractory AML, solid tumors and hematologic malignancies, (Phase 3 trials), onalespib for lung and melanoma, AT7519 for solid tumors, AT13148 for solid tumors, ASTX727 for myelodysplastic syndrome (MDS) and ASTX660 for solid tumors etc among other partner products. Company got acquired by Otsuka pharmaceuticals in 2013 and now operates as a wholly owned subsidiary.
Astex Pharmaceuticals offers Kisqali, Balversa, Truqap, and Tolinapant.
Yes. Astex Pharmaceuticals was acquired by Otsuka in September 2013.